

AMENDMENT (2003)

Page 2

In claim 3, line 2, delete "a" and insert therefor --the--.

In claim 3, line 4, delete "to" and insert therefor --and--.

4. (amended) The pharmaceutical composition according to claim 3 wherein the higher fatty acid glyceride comprises castor oil and [a] the weight ratio of cyclosporin to castor oil is below about 0.16.

an 5. (amended) A pharmaceutical composition [in the form of] comprising a nonirritating emulsion [comprising] of at least one cyclosporin in admixture with castor oil and polysorbate 80 in water suitable for topical application to ocular tissue.

In claim 7, line 2, delete "a" and insert therefor --the--.

In claim 7, line 3, delete "to" and insert therefor --and--.

a³ 8. (amended) The pharmaceutical composition according to claim 7 wherein the weight ratio of [castor oil to] cyclosporin to castor oil is below about 0.16.

C. ~~22.6~~ A pharmaceutical emulsion comprising of cyclosporin A, castor oil, Pemulen, ~~glyceride~~ ^{glycerine, polysorbate 80} and water in amounts sufficient to prevent crystallization of cyclosporin A for a period of up to about nine months, said pharmaceutical emulsion being suitable for topical application to ocular tissue.

23. ⁷~~22.6~~ The pharmaceutical emulsion according to claim ~~22~~ wherein the cyclosporin A is present in an amount of between about 0.05 to and about 0.40%, by weight, the castor oil is present in an amount of between about 0.625%, by weight, and about 5.0%, by weight, the polysorbate 80 is present in an amount of about 1.0%, by weight, the Pemulen is present in an amount of about 0.05%, by weight, and the ~~glyceride~~ ^{glycerine} is present in an amount of about 2.2%, by weight.

C At

⁸~~24.~~ A pharmaceutical emulsion consisting of between about 0.05% and about 0.40%, by weight, cyclosporin A, between about 0.625% and about 5.0%, by weight, castor oil, about 1.0%, by weight, polysorbate 80, about 0.05%, by weight, Pemulen and about 2.2%, by weight, glycerine in water with a pH of between about 7.2 and 7.6 suitable for topical application to ocular tissue.

REMARKS

A new Declaration is submitted herewith in response to the Examiner's noting that the original Declaration was defective. In addition, the specification has been amended to overcome an informality on page 1, indicated by the Examiner.

17